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A B S T R A C T
Inappropriate activation of the IGF (insulin-like growth factor) system has been implicated in the growth
and progression of a number of tumor types. Recent evidence indicates a possible role for the IGF system
in modulating/mediating tumor cell response to hypoxia, a common occurrence in solid tumors, and
particularly in malignant gliomas, causing tumor cells either to die, or to mount a pleiotropic adaptive
response that is mainly orchestrated through activation of the hypoxia-inducible transcription factor
HIF1. Experimental evidence suggests possible links between IGF- and HIF1-dependent signaling
pathways, as well as a role for activated STAT3 in mediating their activities. Interestingly, igf2 is among
the target genes transactivated by HIF1, thereby providing the missing link in a hypothetical autocrine
self-amplifying circuit.
The present study investigates the presence of the IGF-HIF1-VEGF axis in the human glioma cell line
U-87 MG, and characterizes its molecular effectors. Our results show that exogenous IGF-I causes IGF1R
and STAT3 activation, and increases HIF1a protein levels and HIF1 trascriptional activity, inducing VEGF
release; a similar response, mediated by IGF-II release, is observed following HIF1a stabilization. The
existence of an autocrine loop is conﬁrmed by its down-regulation following inactivation of IGF1R (using
the IGF1R-speciﬁc tyrosine kinase inhibitor NVP-AEW541), STAT3 (transfecting the cells with an
expression vector encoding a dominant negative form of STAT3), or HIF1 (using the small molecule
inhibitor YC-1). The ability of NVP-AEW541 to block this circuit could be beneﬁcial in suppressing the
growth and angiogenic potential of hypoxic glial tumors.
 2010 Elsevier Inc. All rights reserved.
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The existence of an autocrine loop involving the IGF (insulin-
like growth factor) system and HIF1 (hypoxia-inducible factor 1) is
emerging as a survival strategy common to different tumor types
[1,2]. The IGF signaling pathway is activated by binding of one of
two soluble polypeptide ligands (IGF-I and IGF-II) to the tyrosine
kinase IGF1R, a tetrameric receptor consisting of two extracellular
a chains and two transmembrane b chains linked by a disulﬁde
bond, bearing a high degree of homology with the insulin receptor
(IR) [3]. Although IGF1R overexpression has been demonstrated in
tumors, its activation is strictly dependent on ligand availability,
which in turn can be regulated by the expression levels of the
decoy receptor IGF2R (also known as the mannose-6-phosphate
receptor) and of six IGF-binding proteins (IGFBPs). IGF1R activa-
tion has been implicated in several key features in malignancy,
including loss of anchorage-dependent growth, evasion of* Corresponding author. Tel.: +39 0331 339415; fax: +39 0331 339459.
E-mail addresses: marzia.gariboldi@uninsubria.it (M.B. Gariboldi),
raffaella.ravizza@gmail.com (R. Ravizza), elena.monti@uninsubria.it (E. Monti).
0006-2952/$ – see front matter  2010 Elsevier Inc. All rights reserved.
doi:10.1016/j.bcp.2010.05.011apoptotic signals, proteolytic degradation of the extracellular
matrix and tumor angiogenesis [4].
Interestingly, the IGF signaling pathway appears to be intimately
connected with HIF1 activation, which indeed seems to mediate at
least part of IGF-induced downstream effects. HIF1 is a hetero-
dimeric transcription factor, the activity of which depends on the
intracellular levels of its inducible a subunit. In the presence of
oxygen, HIF1a is hydroxylated on two critical proline residues
(Pro402 and Pro564) in the so-called oxygen-dependent degradation
domain (ODDD). This modiﬁcation targets the protein for ubiqui-
tylation by an E3 ligase complex (including the Von Hippel-Lindau
tumor suppressor protein) and subsequent proteasomal degrada-
tion [5]. Growth factor tyrosine kinase receptor activation has been
reportedto increaseHIF1a levels, aswell asHIF1activity,underboth
normoxic and hypoxic conditions, mostly through up-regulation of
the PI3K/Akt and Ras/Raf/MAPK pathways [5,6]. HIF1 orchestrates a
pleiotropic adaptive response tohypoxiaby inducing the expression
of more than 100 genes encoding glycolytic enzymes and glucose
transporters (thereby facilitating the glycolytic switch in energy
metabolism typically observed under hypoxic conditions), matrix
metalloproteinases, and angiogenic as well as mitogenic and
survival factors. Most notably, IGF-II is among the growth factors
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growth-promoting autocrine loop [7].
Members of the STAT (signal transducers and activators of
transcription) family might also be involved in mediating signaling
along an IGF-HIF1 axis. In unstimulated cells, STAT proteins are
present in a latent, inactive form; upon engagement of cytokine
and growth factor receptors by their respective ligands, STAT
proteins are recruited to activated receptor complexes and
phosphorylated on tyrosine residues, whereby they dimerize
and translocate to the nucleus, to modulate target gene expression
[8]. Constitutive activation of STAT proteins, and particularly of
STAT3, has been demonstrated in a number of cancer cell lines and
tumors, including gliomas [9,10], presumably due to dysregulation
of growth factor receptor expression and/or activation. However,
the role played by STAT3 in IGF signaling has only been
investigated superﬁcially [11,12].
Conditions required to activate a putative regulatory IGF-HIF1
loop at different points are common in solid tumors. Regions of
intermittent or chronic hypoxia frequently develop within the
tumor mass, due to the fact that proliferating cells rapidly outgrow
existing vessels and to the aberrant function of newly formed tumor
vessel; hypoxia-induced IGF-II release might then sustain the
growth of IGF1R expressing tumors. Similarly, when the circuit is
activatedby increased availability of IGFs, thedownstreameffects of
IGF1R might be greatly ampliﬁed through HIF1 activation.
A number of strategies have been devised to disrupt the IGF
signaling axis, ranging from forced expression of M6P/IGF2R or
IGFBPs to the development of small interfering RNAs, antisense
oligonucleotides, monoclonal antibodies and catalytic inhibitors
targeting IGF1R [13–15]. Similarly, HIF1 has also been considered
as a therapeutic target [16,17]: several small molecule inhibitors
have been described [17]; an antisense oligonucleotide targeting
HIF1a mRNA, as well as a small molecule inhibitor (PX-478) are
currently undergoing phase I clinical trials [18,19]. Merging these
two approaches might lead to mutual potentiation of their effects
in tumors expressing an overactive IGF-HIF1 circuit.
Based on these premises, the present study investigates the role
played by the IGF-HIF1-VEGFaxis in a humangliomacell line, and its
possible regulation through an autocrine circuit. Gliomas are the
most common neoplasms in the adult human brain and they are
frequently characterized by coexistence of intense neoangiogenesis
and hypoxic and necrotic regions; in addition, the IGF system has
been implicated in tumorigenesis in the CNS, and particularly in the
pathogenesis of glial tumors [13,20]. Our results indicate that: (a) an
autocrine loop, involving IGF1R,STAT3,HIF1andIGF-II, exists inU-87
MGcells, regulating tumorcell survival andVEGFproduction;and(b)
the circuit can be effectively disrupted by inhibiting IGF1Ractivation
withtheselectivepyrrolo[2,3-d]pyrimidinederivativeNVP-AEW541
[21], which reduces both cell viability and VEGF release. These
observations suggest that pharmacological targeting of the IGF1R
may provide a signiﬁcant therapeutic beneﬁt, especially in hypoxic
tumors featuring autocrine regulation of the IGF-HIF1 axis.
2. Materials and methods
2.1. Reagents
Standard chemicals and cell culture reagents were purchased
from Sigma–Aldrich srl. (Milan, Italy), unless otherwise indicated;
NVP-AEW541 was generously provided by Novartis (Basel,
Switzerland).
2.2. Cell culture, cytotoxicity studies and HIF1a stabilization
The human glioblastoma cell line U-87 MG (ATCC1 HTB-
14TM) was obtained from the American Type Culture Collection(Manassas, VA, USA), and authenticated by morphological
inspection, growth curve analysis and short tandem repeat
proﬁling, using the Promega PowerPlex1 1.2 system (Promega,
Madison, WI, USA) and the Applied Biosystems Genotyper1 2.0
software (Applied Biosystems, Foster City, CA, USA) for amplicon
analysis. Cells were maintained in DMEM supplemented with
10% fetal bovine serum (Euroclone, Italy), 1% glutamine, 1%
antibiotic mixture, 1% sodium pyruvate, 1% non-essential
aminoacids, at 37 8C in a humidiﬁed 5% CO2 atmosphere and
were routinely checked for Mycoplasma infection, using the
Mycoplasma PlusTM PCR Primer Set (Stratagene, Agilent Tech-
nologies, La Jolla, CA).
To assess cell survival following NVP-AEW541 exposure,
4  104 U-87 MG cells/well were seeded onto 24-well plates and
allowed to grow for 24 h before treatment with different NVP-
AEW541 concentrations (0.25, 0.5, 1.0 and 2.5 mM). After 24 h
(and subsequently at 48 and 72 h for growth curves), cells from
3 replicate wells per treatment were detached by trypsinization
and resuspended in PBS containing 0.2% Trypan blue; viable cells
were counted using a Bu¨rker hemocytometer following 10 min
incubation.
To achieve HIF1a stabilization, cells were exposed to 50 mM
CoCl2 for 24 h, a condition thatmimics hypoxia by inhibiting prolyl
hydroxylation of the ODDD and its subsequent interactionwith the
Von Hippel-Lindau protein [22].
2.3. Vectors and transfections
U-87MG cells were transiently transfectedwith an expression
plasmid (pEF-HA-STAT3F) containing a full-length cDNA encod-
ing hemagglutinin peptide (HA)-tagged STAT3F, a dominant
negative form of STAT3 in which Tyr705 is replaced by phenylala-
nine, subcloned into a pEF-BOS expression vector (originally
provided by Prof. S. Nagata, University of Osaka Medical School,
Japan [23]); control cells were transfected with the pEF-BOS
plasmid. pEF-HA-STAT3F was a generous gift from Prof. T. Hirano
(Department of Molecular Oncology, University of Osaka Medical
School, Japan [24]). Log-phase growing cells (5  106) were
harvested and transfected with 30 mg of DNA, using an EasyJet
electroporator system (Equibio, Ashford, UK), under conditions
optimized according to the manufacturer’s instructions (200 V,
1500 mF). All experiments were performed starting 48 h after
transfection.
The pBabe-STAT3C expression vector, containing a cDNA
encoding a constitutively activated form of STAT3, was a generous
gift from J. Bromberg et al. [25] and was transfected into U-87 MG
cells by lipofection, using Lipofectamine 20001 (Invitrogen,
Carlsbad, CA, USA). Brieﬂy, 1  106 cells were seeded onto
100 mm Petri dishes and allowed to grow for 24 h before
lipofection with the pBabe-STAT3C plasmid; control cells were
transfectedwith the ‘‘empty’’ pBabe plasmid. STAT3C expression in
transfected cells persisted for 6–8 days; all the experiments were
performed within 5 days after transfection.
U-87/HRP-EGFP cells were obtained from U-87 MG cells
by transient transfection with a plasmid containing the
EGFP (enhanced green ﬂuorescent protein) cDNA under the
control of an artiﬁcial hypoxia-responsive promoter (HRP),
consisting of ﬁve copies of a 35-bp fragment from the HRE of the
human VEGF gene and a human cytomegalovirus (CMV)
minimal promoter (kindly provided by Dr. Y. Cao) [26]. Cells
were seeded onto 6-well plates (3.5  105 cells/well) and
allowed to attach for 24 h before lipofection using Lipofectamine
20001. EGFP expression in transfected cells (following HIF1a
stabilization with CoCl2 at 50 mM for 24 h) persisted for 6–8
days; all the experiments were performed within 5 days after
transfection.
Fig. 1. Effect of IGF-I (100 ng/ml for 15 min) and of inhibition of IGF1R tyrosine
kinase activity by NVP-AEW541 (1mM for 24 h) on: (A) IGF1R and STAT3
phosphorylation and IGF1R, STAT3 and HIF1a protein levels; (B) HIF1
transcriptional activity; (C) VEGF release in U-87 MG human glioma cells.
Mean  SE of 3 independent experiments. Actin levels were determined as a
control for equal gel loading.
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STAT3-dependent transcriptional activity was assessed in
nuclear extracts obtained from U-87 MG (parental), U-87-STAT3C
and U-87-pBabe cells, using the TransAMTM STAT3 Trascription
Factor Assay Kit (Active Motif, Carlsbad, CA, USA) according to the
manufacturers’ instructions. HIF1-dependent transcriptional ac-
tivity was determined in U-87/HRP-EGFP cells following exposure
to CoCl2 (50 mM for 24 h) or IGF-I stimulation (100 ng/ml for
15 min), in the presence or absence of 1mMNVP-AEW541 for 24 h.
Cell samples were analyzed with a FACSCaliburTM ﬂow cytometer
(Becton Dickinson, Mountain View, CA, USA), equipped with a
15 mW, 488 nm and air-cooled argon ion laser. At least 10,000
events were analyzed for each sample and data were processed
using CellQuestTM software (Becton Dickinson). EGFP ﬂuorescence
data were collected, using log ampliﬁcation, in the FL1 channel
(530/30) and ﬂuorescence intensity was expressed as mean
ﬂuorescence channel (MFC).
2.5. Immunoprecipitation and Western blot analysis
Activation of IGF1R and of STAT3 was evaluated by immuno-
precipitation of cell lysates obtained from U-87MG, U-87 pEF-BOS
and U-87 STAT3F cells, with or without exposure to IGF-I (100 ng/
ml for 15 min) and/or NVP-AEW541 (1mM for 24 h). Lysis buffer
composition was as follows: NaCl 120 mM, NaF 25 mM, EDTA
5 mM, EGTA 6 mM, sodium pyrophosphate 25 mM, in Tris–HCl
50 mM pH 7.5, containing PMSF 0.2 mM, Na3VO4 1 mM, pheny-
larsine oxide 1 mM, NP-40 1% and protease inhibitor cocktail 10%).
Protein concentration was determined by the bicinchoninic acid
method using the BCATM Protein Assay Kit (Pierce, Rockford, IL,
USA) and 1000mg of protein were incubated overnight with the
primary antibody anti-IGF1R or anti-STAT3 (rabbit polyclonal
antibodies, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA—
SCB) at 4 8C and immunoprecipitated following 2 h incubation
with protein G-SepharoseTM (Sigma–Aldrich, Milan, Italy). Proteins
were then dissolved in sample buffer and separated by SDS-PAGE,
transferred onto ImmobilonTM-P PVDF membranes (Millipore,
Bedford, MA, USA) and Western blot analysis was performed
incubating the membranes with a mouse monoclonal anti-pTyr
antibody (PY20, SCB) to evaluate the phosphorylation state of the
receptor, or with a rabbit anti-pSTAT3 polyclonal antibody (Cell
Signaling Technology, Danvers, MA, USA). Total IGF1R or STAT3
protein levels were obtained by incubating the same membranes
with anti-IGF1R or anti-STAT3 rabbit polyclonal antibodies.
Proteins were visualized using peroxidase-conjugated secondary
antibodies and the SuperSignal1West Pico Chemiluminescent
Substrate (Pierce).
The effects of IGF-I and/or NVP-AEW541 onHIF1a expression in
normoxia and following HIF1a stabilization with CoCl2 (50mM for
24 h) were determined by Western blot analysis of total cell
lysates. Fifty microgram of proteins were separated and trans-
ferred onto ImmobilonTM-P membranes and the membranes were
incubated with a mouse anti-HIF1amonoclonal antibody (Becton
Dickinson, San Jose, CA, USA). Equal loading of the samples was
veriﬁed by re-probing the blots with a mouse monoclonal anti-
actin antibody (SCB).
2.6. VEGF and IGF-II release
VEGF levels were measured in supernatants from U-87 MG cell
cultures following exposure to NVP-AEW541 (1.0 mM for 24 h) and
IGF-I (100 ng/ml for 15 min), using the Human ELISA VEGF
Development Kit (PeproTech, Inc., Rocky Hill, NJ, USA), according
to the manufacturer’s instructions. IGF-II levels were measured in
supernatants from U-87 MG cell cultures following 24-h exposureto CoCl2 (50 mM) and YC-1 (10mM) using a Human Total IGF-II
DuoSet1 ELISA System (R&D Systems, Inc., Minneapolis, MN).
Growth factor release was quantitated colorimetrically using a
Universal Microplate Reader EL800 (BioTek, Winooski, VT, USA) at
405 nm for VEGF and at 450 nm for IGF-II.
2.7. Statistical analysis
Statistical analysis of the data was performed by two-way
ANOVA, with Bonferroni’s post-test for multiple comparisons.
3. Results
3.1. IGF1R stimulation causes STAT3 activation, increases HIF1a
protein levels and HIF1 activity, and induces VEGF release
Fig. 1A shows the effects of exogenous IGF-I, with orwithout the
IGFR1 inhibitor NVP-AEW541, on tyrosine phosphorylation of
IGF1R and STAT3, and on HIF1a protein levels, as assessed by
immunoprecipitation and/orWestern blot. Immunoreactive bands
corresponding to all three proteins were detected in U-87MG cells
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creased following exposure to IGF-I (100 ng/ml for 15 min). As
expected, treatment with NVP-AEW541 (1mM for 24 h, including
the last 15 min with IGF-I) caused pTyr-IGF1R to revert to baseline
levels. Interestingly, this treatment also reduced the levels of
pTyr705-STAT3 and of HIF1a, suggesting that IGF1R acts upstream
of both. Total IGF1R and STAT3 protein levels were unchanged.
HIF1 transcriptional activity was also up-regulated by IGF-I, as
indicated by the shift of the EGFP ﬂuorescence peak towards higher
intensity values, and inhibited by NVP-AEW541, with the
ﬂuorescence peak reverting to control values (Fig. 1B). This ﬁnding
is indirectly conﬁrmed by increased VEGF release following IGF-I
treatment and by its inhibition in the presence of NVP-AEW541
(Fig. 1C).
3.2. STAT3 inhibition blocks HIF1 activation and VEGF release
Fig. 2A shows STAT3, pSTAT3 and HIF1a levels in U-87MG cells
following transfection of the pEF-HA-STAT3F expression vector,
encoding a dominant negative form of STAT3 (U-87 STAT3F), or
with the ‘‘empty’’ vector pEF-BOS (U-87 pEF-BOS), with or without
IGF-I stimulation. As expected, pSTAT3 levels were lower in U-87
STAT3F than in U-87 pEF-BOS control cells under baseline
conditions; in contrast, total STAT3 levels were similar in the
two cell lines, and were not modiﬁed by treatment with IGF-I.
Following IGF-I exposure (100 ng/ml for 15 min), the activated
form of STAT3 was found to increase in U-87 pEF-BOS cells, while
pSTAT3 levels were unaffected in U-87 STAT3F cells (Fig. 2A).
Accordingly, HIF1a protein levels, as well as VEGF release (Fig. 2B),Fig. 2. Effect of IGF-I on: (A) total and phosphorylated STAT3 and HIF1a protein
levels and (B) VEGF release in U-87 MG cells transfected with a dominant negative
form of STAT3 (U-87 STAT3F); cells transfected with the ‘‘empty’’ pEF-BOS vector
(U-87 pEF-BOS) were used as controls. Transcriptional activity of STAT3 (panel C)
and HIF1a protein levels (panel D) in U-87 MG cells transfected with a
constitutively active form of STAT3 (U-87 STAT3C); cells transfected with the
‘‘empty’’ pBabe vector (U-87 pBabe) were used as controls. Mean  SE of 3
independent experiments. Actin levels were determined as a control for equal gel
loading.were also increased in U-87 pEF-BOS cells following exposure to
IGF-I, whereas no increase was observed in U-87 STAT3F cells,
indicating that STAT3 inhibition prevents IGF-I-induced HIF1a
accumulation (and HIF1 transcriptional activation). The role
played by STAT3 in HIF1a accumulation is conﬁrmed by the
ﬁnding that, in U87-STAT3C cells, expressing a constitutively
active form of the transcription factor (Fig. 2C), HIF1a protein
levels are increased under normoxic conditions, as compared with
U-87 pBabe cells (Fig. 2D).
3.3. HIF1a stabilization causes IGF1R activation by inducing
IGF-II release
In line with the literature [22], exposure of U-87 MG cells to
CoCl2 (50mM for 24 h) induces a marked increase in HIF1a levels
(Fig. 3A), due to decreased degradation by the proteasome. Under
these experimental conditions, pTyr-IGF1R levels are also in-
creased, even in the absence of added exogenous IGFs. The addition
of YC-1 (10 mM for 24 h), a guanylyl cyclase activator that has been
shown to decrease HIF1a accumulation and HIF1 activity [27–29],
reduces HIF1a protein levels almost to baseline values. Interest-
ingly, pTyr-IGF1R, but not total IGF1R, levels are also reduced by
YC-1 treatment, indicating that HIF1 plays a causal role in IGF1R
activation. In agreement with this ﬁnding, and with the putative
role of STAT3 in the IGF1R-HIF1-IGF-II circuit, pTyr705-STAT3 levels
are increased following exposure to CoCl2 and this effect is
prevented by simultaneous exposure to YC-1. The hypothetical
role of IGF-II in the circuit is conﬁrmed by the ﬁndings reported in
Fig. 3B, showing IGF-II release fromU-87MG cells following HIF1a
stabilization by CoCl2, an effect that is also inhibited by YC-1. These
results point to IGF-II as the molecular effector actually mediating
HIF1-induced IGF1R activation.
3.4. NVP-AEW541 inhibits glioma cell growth and disrupts the
autocrine loop initiated by HIF1a stabilization
Fig. 4A shows the growth curves (0–72 h) obtained for U-87MG
glioma cells in the absence or presence of different NVP-AEW541
concentrations, and indicates that selective inhibition of IGF1R
activity decreases cell growth in a dose-dependent fashion; IC50
values extrapolated from dose response curves at 24 and 72 h are
2.07  0.050 and 0.99  0.021 mM, respectively. In addition, NVP-
AEW541 (1 mM for 24 h) signiﬁcantly inhibits the growth of U-87MG
cells in which HIF1a has been stabilized by exposure to CoCl2 (50 mM
for 24 h) (Fig. 4B). On amolecular level, under the same experimental
conditions NVP-AEW541 is not only able to prevent IGF1R activation
in the absence of added IGFs, but also to reduce HIF1a accumulation
(Fig. 5A), which suggests disruption of a positive feedback loop, very
likely sustained by IGF-II release (see above). Accordingly, HIF1-
transcriptional activity and HIF-induced VEGF release, which are
signiﬁcantly increased following exposure to CoCl2, are markedly
reduced by co-treatment with NVP-AEW541 (Fig. 5B and C).
4. Discussion
A large body of converging evidence from laboratory investiga-
tions and population studies implicates the IGF system in the
development of malignancies, including gliomas [3,13]. IGF-I has
been shown to affect both proliferation and migration of
glioblastoma cell lines in vitro, and IGF1R inhibition has been
reported to contribute to growth suppression of primary cell lines
derived from human high-grade gliomas [30,31]. In contrast to
other growth factor receptors, and most notably to EGFR (which is
also involved in gliomagenesis), IGF1R activation in tumors is
hardly ever due to gene ampliﬁcation or point mutations. Rather,
constitutive receptor activation is commonly caused by increased
Fig. 3. Effect of exposure to the hypoxia mimic CoCl2 (50 mM for 24 h), with or
without the HIF1 inhibitor YC-1 (10mM for 24 h), on: (A) HIF1a, IGF1R and STAT3
protein levels, and IGF1R and STAT3 phosphorylation; and (B) on the release of IGF-
II in U-87 MG human glioma cells. Mean  SE of 3 independent experiments. Actin
levels were determined as a control for equal gel loading.
Fig. 4. Effect of NVP-AEW541 on the growth of U-87 MG human glioma cells. (A)
Growth curves obtained in the presence of different NVP-AEW541 concentrations;
mean  SE of 3 independent experiments. (B) Effect of NVP-AEW541 (1 mM for 24 h)
on survival rates in U-87 MG cells, with or without HIF1a stabilization with CoCl2
(50 mM for 24 h); mean  SE of 4 independent experiments.
Fig. 5. Effect of NVP-AEW541: (A) HIF1a, IGF1R and STAT3 protein levels, and IGF1R
and STAT3 phosphorylation; (B) HIF1 transcriptional activity; (C) VEGF release in U-
87 MG human glioma cells (A and C) or U-87 HRP/EGFP (B) cells, with or without
HIF1a stabilization with CoCl2 (50 mM for 24 h); mean  SE of 3 independent
experiments. Actin levels were determined as a control for equal gel loading.
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decreased levels of IGF-binding proteins (IGFBPs) and/or IGF2R (a
decoy receptor primarily sequestering IGF-II), or increased release
of IGFs through paracrine or autocrine processes [15]. The working
hypothesis underlying the present study is that autocrine
activation of IGFR1 is a likely occurrence in high-grade gliomas,
where hypoxic conditions frequently prevail, in spite of active
neoangiogenesis, due to high proliferation rates and to the
aberrant structure of newly formed vessels [32,33]. In IGF1R-
expressing cells, hypoxia may trigger a positive self-regulatory
circuit mediated by HIF1 activation and subsequent release of IGF-
II [7], an important by-product of the circuit being increased VEGF
release. If such a circuit could be demonstrated to operate in
gliomas, this would constitute a powerful rationale for using one of
the several recently developed IGF1R-targeting agents in the
clinical management of this tumor type. To verify our hypothesis,
we ﬁrst demonstrated that IGF1R activation by exogenously
applied IGF-I was indeed able to increase the levels of HIF1a, the
inducible subunit controlling HIF1 transcriptional activity, in
human U-87 MG glioblastoma cells under normoxic conditions; as
a result, HIF1 transcriptional activity also increased, as demon-
strated using a GFP-expressing reporter construct (Fig. 1B) and by a
signiﬁcant increase in VEGF release (Fig. 1C). All these effects were
abrogated, or signiﬁcantly reduced, by exposure toNVP-AEW541, a
pyrrolopyrimidine derivative selectively targeting the catalytic
domain of IGF1R [21]. These observations are in agreement with
ﬁndings reported for other tumors/cell lines, corroborating the
existence of an IGF-HIF1-VEGF axis in different tumor types
[6,11,34,35]. Growth factor receptor activation is known to
increase HIF1a levels in an oxygen-independent fashion, and this
effect is generally attributed to increased protein synthesis via the
PI3K/Akt/mTOR pathway [36]. In the present study, the contribu-
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addressed; however, it is worth noting that, in the case of IGF1R,
the ‘‘canonical’’ model for PI3K/Akt/mTOR activation involves
intracellular engagement of insulin receptor substrates (IRS) 1 and
2 to the activated IGF1R, which in turn leads to recruitment of the
regulatory subunit (p85) of PI3K, followed by activation of the
p110 catalytic subunit [37]. As mTOR is known to downregulate
IRS-1/2 [38,39], activation of this pathway would have a self-
limiting impact on HIF1a synthesis. However, other signaling
cascades downstream of IGF1R might lead to HIF1 activation:
besides the Ras/Raf/MEK/ERK pathway, known to enhance HIF1
activity by phosphorylating the C-terminal transactivating domain
of HIF1a and facilitating interactions with transcriptional co-
activators [36], the JAK/STAT pathway has also been implicated as
an importantmediator in the IGF-dependent signaling in a number
of tissues and tumor types [40]. Of note, constitutive activation of
STAT3, as indicated by Tyr705 phosphorylation, has been reported
in brain tumors [10,41], where it may play a major role in driving
angiogenesis, but up to now its role in IGF signaling has not been
extensively investigated in this tumor type. In our experimental
model, constitutively active STAT3C increases HIF1a protein
levels, thereby supporting that STAT3-dependent signaling path-
ways contribute to HIF1 activation. In addition, our data indicate
that in U-87 MG glioblastoma cells STAT3 acts downstream of
IGF1R activation and upstream of HIF1, based on the ability of DN-
STAT3F to prevent the increase in HIF1a normally observed upon
exposure to exogenous IGF-I (Fig. 2). Mechanistically, the effect of
STAT3 on HIF1a levels seems to depend on a variation of the
canonical IGF1R-PI3K-AKT-mTOR model outlined above: STAT3
can be recruited by the IGF1R independent of IRS1/2 [12] and
subsequently regulates Akt1 expression [42], which may increase
HIF1a protein synthesis. In addition, STAT3 has been shown to
increase HIF1a mRNA levels [43] and to stabilize HIF1a by
inhibiting its binding to the VonHippel-Lindau protein [44]. Finally
STAT3 andHIF1a have been shown to formamultiprotein complex
with transcription coactivators CBP/p300 and Ref-1/Ape, that
binds to the VEGF promoter and regulates gene expression [45].
Having established that an IGF-(STAT3)-HIF1 axis operates in U-
87 MG cells, we then proceeded to investigate the existence of an
autocrine circuit involving these same players. To this aim, we
induced HIF1 activation independent of IGF1R stimulation, by
exposing the cells to CoCl2 to stabilize HIF1a, and observed that
under these experimental conditions IGF1R was activated in the
absence of exogenously added ligands. Importantly, such activa-
tionwas prevented by YC-1, a guanylyl cyclase activator that is also
known to inhibit HIF1a accumulation and HIF1 transcriptional
activity [27–29], indicating that HIF1 activation is an obligatory
step in the circuit (Fig. 3). Incidentally, this experiment also
conﬁrmed the involvement of STAT3 in this signaling axis, based on
the increase in pTyr705-STAT3 induced by CoCl2 and the ability of
YC-1 to prevent it. The observed cell-autonomous activation of
IGF1R strongly suggests that autocrine stimulation of the receptor
occurs following HIF1-induced release of speciﬁc ligand(s). Indeed,
CoCl2-stimulated cells were found to release IGF-II, the product of a
recognized HIF1 target gene; IGF-II release was signiﬁcantly
suppressed by YC-1 at the same concentration that was shown to
block IGF1R and STAT3 activation. Similar autocrine regulatory
loops have been described in cell lines and xenografts derived from
other tumor types, where they appear to play a key role in tumor
cell survival and angiogenesis [1,2,11]. It is important to underline
that the circuit can be set in motion by different stimuli besides
IGF1R stimulation, including HIF1 activation by hypoxia and/or
growth factors and STAT3 activation by growth factor or cytokine
receptors. Thus, in principle, strategies directed at any one step of
the circuit, including targeting HIF1 activity with small molecules
or nucleotide-based agents [17,18], or STAT3 activation usinginhibitors of upstream kinases [46,47] should have a disruptive
effect on the whole circuit. As antibodies and small molecule
tyrosine kinase inhibitors targeting IGFR1 are by far the most
advanced in the clinic [48,49], in the present study we decided to
use NVP-AEW541 to verify how blocking this step in the circuit
would affect the survival and pro-angiogenic features of glioblas-
toma cells. Recent data by Moser et al. indicate that in IGF-I-
stimulated pancreatic cancer cell inhibition of IGF1R activation by
NVP-AEW541 was accompanied by decreased STAT3 phosphory-
lation and led to reduced IGF-dependent growth [11]; inhibition of
tumor growth and angiogenesis was also observed in mice bearing
pancreatic cancer xenografts following NVP-AEW541 treatment in
vivo. In U-87 MG cells, we found that NVP-AEW541 inhibited cell
growth in a time and concentration-dependent fashion (Fig. 4A).
Cell survival was also inhibited in U-87 MG cells following HIF1a
stabilization with CoCl2 (Fig. 4B); however, the extent of growth
inhibition by NVP-AEW541 was not signiﬁcantly affected by the
HIF1a-stabilizing treatment, even though NVP-AEW541 was
indeed able to reduce HIF1a levels in CoCl2-treated cells
(Fig. 5A). So, from our results it would appear that, while IGF1R
receptor inhibition has a distinct effect on U-87 MG cell survival,
the fact that HIF1a stabilization is also signiﬁcantly prevented
does not result in any added beneﬁt in terms of growth inhibition,
which therefore seems to depend on disruption of IGF1R signaling
as a whole rather than solely on disruption of the described IGF-
(STAT3)-HIF1 circuit. This is not altogether surprising, given the
multiple signaling pathways downstream of IGF1R that might
contribute to cell survival and that are curtailed by NVP-AEW541,
whereas blocking HIF1a accumulation (by RNA interference) has
been shown to cause only marginal cytotoxicity in glioma cells in
vitro [50]. In contrast, blocking IGFR1 activation caused by HIF1
stabilization resulted in a signiﬁcant decrease in VEGF release in
NVP-AEW541-treated cells, whereas no effect was observed on
VEGF release under baseline conditions (i.e. when HIF1a levels
were not artiﬁcially elevated by CoCl2). Therefore, based on these
results, activation of the circuit does seem to be crucial in
maintaining the angiogenic potential of U-87 MG cells, as assessed
by their ability to release signiﬁcant amounts of VEGF. To support
this conclusion, silencing HIF1a by RNA interferencewas shown to
inhibit the in vivo growth of xenografts obtained from the same
glioma cell lines, the survival ofwhichwas onlyweakly impaired in
vitro [50],which strongly suggests that the pro-angiogenic effect of
HIF1 is crucial for the in vivo growth of glial tumors, rather than its
ability to directly stimulate intracellular pro-survival mechanisms.
On the other hand, the fact that blocking IGFR1 is able to curb HIF1
activation should not be overlooked, in view of its possible
implications for the design of drug combinations. HIF1 is well
known for its role as a resistance factor impairing the activity of a
number of cytotoxic agents in several tumor types [51,52]. More
speciﬁcally, in vitro studies on glioma cell lines indicate that HIF1
activation signiﬁcantly impairs the cytotoxicity of two of the very
few agents that show some effect against this tumor type, namely
temozolomide and BCNU [53,54], and this scenario is very likely to
occur in vivo in glioblastomas, as mentioned above. Thus, blocking
IGF1R signaling with NVP-AEW541, or with one of the several
agents targeting this receptor that are currently undergoing
clinical trials, could be successfully exploited in the clinical
management of gliomas for its double effect on tumor angiogenesis
and on drug sensitivity of hypoxic cells.
To conclude, our data support the hypothesis that in U-87 MG
human glioma cells a self-amplifying autocrine loop exists, that
can be activated by IGFs and hypoxia, as well as by signaling
pathways that impinge on STAT3, and that can lead to enhanced
angiogenic potential via an increase in VEGF release (Fig. 6).
Inhibition of IGF1R tyrosine kinase activity, e.g. by using NVP-
AEW541, can disrupt such a circuit, even when the primary trigger
Fig. 6. Proposed model for a self-regulatory circuit involving the IGF system, STAT3
and HIF1, and regulating cell proliferation and angiogenesis in human U-87 MG
glioma cells.
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ligands, thereby representing a potential therapeutic approach,
especially for the management of solid tumors characterized by
hypoxic regions.
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